North America $3.62 Bn Nuclear Medicine Market by Country, Competition, Forecast & Opportunities, 2019-2023 & 2024-2029
August 26, 2024 10:52 ET
|
Research and Markets
Dublin, Aug. 26, 2024 (GLOBE NEWSWIRE) -- The "North America Nuclear Medicine Market, By Country, Competition, Forecast & Opportunities, 2019-2029F" report has been added to ...
Radiotherapy, Radiopharmaceuticals and Nuclear Medicine Global Markets Research 2021-2029: Increasing Demand in Developing Regions, Applications Beyond Oncology, Theranostics Gaining Traction
August 21, 2024 06:57 ET
|
Research and Markets
Dublin, Aug. 21, 2024 (GLOBE NEWSWIRE) -- The "Radiotherapy, Radiopharmaceuticals and Nuclear Medicine: Global Markets" report has been added to ResearchAndMarkets.com's offering.The global market...
Canada Nuclear Medicine Market Analysis Report 2024-2030, Featuring Nordion, Lantheus Medical Imaging, Cardinal Health, Jubilant Life Sciences, Isologic Innovative Radiopharmaceuticals & Curium Pharma
January 24, 2024 05:46 ET
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Canada Nuclear Medicine Market Size, Share & Trends Analysis Report by Product (Diagnostic, Therapeutic), Application (Oncology, Bone Metastasis,...
Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer
December 18, 2023 07:30 ET
|
POINT Biopharma
BEDFORD, Mass. and INDIANAPOLIS, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus) (NASDAQ: LNTH) and POINT Biopharma Global Inc. (POINT) (NASDAQ: PNT) today announced...
TeleDaaS™ Launches as Premier Provider of Dosimetry as a Service for Clinical Research Organizations
November 26, 2023 08:00 ET
|
TeleDaas PLLC
TeleDaaS revolutionizes radiopharmaceutical research by delivering highly-scalable, clinical-grade dosimetry to accelerate cancer treatment breakthroughs.
POINT Biopharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights
November 13, 2023 07:30 ET
|
POINT Biopharma
INDIANAPOLIS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to...
Global Radiopharmaceuticals Strategic Analysis Report 2023: Market to Reach $14.3 Billion by 2030 - Emergence of Radiotheranostics as Dual-Functioning Radiopharmaceuticals Bolsters Growth
October 09, 2023 05:48 ET
|
Research and Markets
Dublin, Oct. 09, 2023 (GLOBE NEWSWIRE) -- The "Radiopharmaceuticals - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.Global Radiopharmaceuticals Market...
POINT Biopharma and Athebio Announce Partnership to Develop Designed Ankyrin Repeat Protein Targeted Radioligands
September 18, 2023 08:00 ET
|
POINT Biopharma
INDIANAPOLIS and SCHLIEREN-ZURICH, Switzerland, Sept. 18, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery,...
Radiopharmaceutical Theranostics Market Projected to Reach $3.44 Billion by 2028, Fueled by Growing Cancer Incidence and Personalized Medicine
September 18, 2023 07:48 ET
|
Research and Markets
Dublin, Sept. 18, 2023 (GLOBE NEWSWIRE) -- The "Radiopharmaceutical Theranostics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type, Radioisotope, Source, Application,...
POINT Biopharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights
August 14, 2023 07:30 ET
|
POINT Biopharma
Enrollment in PNT2002's SPLASH trial is complete and topline data is expected in the fourth quarter of 2023 Next-generation actinium-225 PSMA program PNT2001 phase 1 trial design released; first...